Prostate Cancer Clinical Trials in Rochester, New York

7 studies are recruiting for prostate cancer in Rochester, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

   Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Rochester - Wilmot Cancer Institute, Rochester, New York

   Locations

   10 in total

   Run by

   Nammi Therapeutics Inc

   See if you can join NCT06582017 on ClinicalTrials.gov

2. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

   The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   University of Rochester Medical Ctr, Rochester, New York

   Locations

   95 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06855277 on ClinicalTrials.gov

3. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

   This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Rochester Medical Center, Rochester, New York

   Locations

   337 in total

   Run by

   Pfizer

   See if you can join NCT07028853 on ClinicalTrials.gov

4. A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

   This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.

   Stage

   EARLY_Phase 1

   Ages

   18 to 70

   Site

   Wilmot Cancer Institute, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT05530655 on ClinicalTrials.gov

5. Stratagen Quantitative Prostate MRI Platform Pilot Study

   The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions. * What severe problems, if any, occur because of the use of the Stratagen Quan…

   Stage

   Not phased

   Ages

   40 to 90

   Site

   Urology Clinic at Sawgrass, Rochester, New York

   Locations

   2 in total

   Run by

   Stratagen Bio, Inc.

   See if you can join NCT06985238 on ClinicalTrials.gov

6. 4-aminopyridine Treatment for Nerve Injury

   To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.

   Stage

   Phase 2

   Ages

   45 to 75

   Site

   University of Rochester, Rochester, New York

   Locations

   2 in total

   Run by

   John Elfar

   See if you can join NCT03701581 on ClinicalTrials.gov

7. Effect of Text Message Reminders on M-ISI Score After Prostate Surgery

   The purpose of this study is to compare post-prostatectomy incontinence via Michigan Incontinence Score Index in patients receiving daily text message reminders for pelvic floor exercises when compared to those not receiving text reminders.

   Stage

   Not phased

   Ages

   18 and older

   Site

   158 Sawgrass clinic; Suite 3100, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT07071207 on ClinicalTrials.gov